[Advances in  the study of Momordica charantia L].
Liu
Xia
X
Research Center for Development of New Drugs, Beijing Institute of Technology, Beijing 100081, China
Li
Shengcai
S
Feng
Changgen
C
Yan
Dejun
D
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000302:isolation & purification / Q000494:pharmacology / Q000627:therapeutic use; D002554:Cerebrosides / Q000302:isolation & purification; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D004365:Drugs, Chinese Herbal / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007004:Hypoglycemic Agents / Q000302:isolation & purification / Q000494:pharmacology* / Q000627:therapeutic use; D029777:Momordica charantia / Q000737:chemistry; D010598:Pharmacognosy; D008517:Phytotherapy; D010946:Plants, Medicinal / Q000737:chemistry
D000972:Antineoplastic Agents, Phytogenic; D002554:Cerebrosides; D004365:Drugs, Chinese Herbal; D007004:Hypoglycemic Agents